This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Buying shares of the right companies -- those that can generate generous returns for decades -- will help significantly ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2024 results , with sales up 5.6% year on year to $15.1 billion. Its ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Looking at the universe of stocks we cover at Dividend Channel, on 1/15/25, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and Phillips Edison & Co Inc (Symbol: PECO) will all trade ...

Regarding distributions, we view AbbVie’s dividends and share repurchases as about right. Since being divested from Abbott, AbbVie has largely focused on a dividend payout ratio close to 50% ...

The dividend is significant to AbbVie: The company is a Dividend King, with a decades-long history of yearly increases from when it was still part of Abbott Labs. Investors can probably expect mid ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...